Recursion announces clinical trial approvals for REC-3565 and REC-4539, targeting B-cell malignancies and small-cell lung cancer. Recursion announced that the UK Medicines and Healthcare Products ...
The last time I wrote about Recursion Pharmaceuticals, Inc. (RXRX), it was in a Seeking Alpha article entitled “Recursion: Path Forward For REC-994 Remains Despite Mixed Response.” In the article, I ...
On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...
The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback